3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Follicular
2
Pyloric Stenosis, Hypertrophic
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Rituximab
24
Lenalidomide
12
Cyclophosphamide
12
fludarabine phosphate
10
Peripheral Blood Stem Cell Transplantation
10
Mycophenolic Acid
6
Cyclosporine
6
Whole-Body Irradiation
5
Radiotherapy
5
Filgrastim
5
ibritumomab tiuxetan
4
Indium
4
Etoposide
4
romidepsin
3
Sirolimus
3
Prednisone
3
Pentostatin
3
Methotrexate
3
Melphalan
3
In Situ Hybridization, Fluorescence
3
Gene Expression Profiling
3
Everolimus
3
Busulfan
3
Bortezomib
3
Bendamustine Hydrochloride
3
zanubrutinib
2
venetoclax
2
veltuzumab
2
temsirolimus
2
obinutuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, B-Cell, Marginal Zone
×
R-CHOP protocol
×
Clear all
NCT04542824
2026-05-05
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled